inclusion criteria: * histologically confirmed cancer diagnosis * ongoing systemic antineoplastic treatment irrespective of application route * age ≥ 18 years * life expectancy of at least 3 months * adequate renal, cardiac and liver function * corrected qt time (qtc) ≤ 450 ms * eastern cooperative oncology group (ecog) performance status of \< 3 * capable of understanding the study and giving informed consent * negative covid-19 test at study entry as measured by routine testing

inclusion criteria: * histologically confirmed cancer diagnosis * ongoing systemic antineoplastic treatment irrespective of application route * age ≥ 18 years * life expectancy of at least 3 months * adequate renal, cardiac and liver function * corrected qt time (qtc) ≤ 450 ms * eastern cooperative oncology group (ecog) performance status of \< 3 * capable of understanding the study and giving informed consent * negative covid-19 test at study entry as measured by routine testing

inclusion criteria: - histologically confirmed cancer diagnosis - ongoing systemic antineoplastic treatment irrespective of application route - age ≥ 18 years - life expectancy of at least 3 months - adequate renal, cardiac and liver function - corrected qt time (qtc) ≤ 450 ms - eastern cooperative oncology group (ecog) performance status of < 3 - capable of understanding the study and giving informed consent - negative covid-19 test at study entry as measured by routine testing

inclusion criteria: - histologically confirmed cancer diagnosis - ongoing systemic antineoplastic treatment irrespective of application route - age ≥ 18 years - life expectancy of at least 3 months - adequate renal, cardiac and liver function - corrected qt time (qtc) ≤ 450 ms - eastern cooperative oncology group (ecog) performance status of < 3 - capable of understanding the study and giving informed consent - negative covid-19 test at study entry as measured by routine testing